These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26153237)

  • 1. Emerging drugs for the treatment of myelofibrosis.
    Geyer HL; Mesa RA
    Expert Opin Emerg Drugs; 2015; 20(4):663-78. PubMed ID: 26153237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches in myelofibrosis.
    Barosi G; Rosti V; Vannucchi AM
    Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing new therapies and their overall impact in myelofibrosis.
    Mesa RA
    Hematology Am Soc Hematol Educ Program; 2010; 2010():115-21. PubMed ID: 21239780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging drugs for myelofibrosis.
    Atallah E; Verstovsek S
    Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for the treatment of Myelofibrosis.
    Shreenivas A; Mascarenhas J
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):37-49. PubMed ID: 29480036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory agents in myelofibrosis.
    Tabarroki A; Tiu RV
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies.
    Tibes R; Mesa RA
    J Hematol Oncol; 2014 Mar; 7():18. PubMed ID: 24598114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
    Mesa RA; Kantarjian H; Tefferi A; Dueck A; Levy R; Vaddi K; Erickson-Viitanen S; Thomas DA; Cortes J; Borthakur G; Pardanani AD; Estrov Z; Verstovsek S
    Cancer; 2011 Nov; 117(21):4869-4877. PubMed ID: 21480207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Therapies for Myelofibrosis.
    Pettit K; Odenike O
    Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
    Mesa RA; Tefferi A
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for the treatment of myelofibrosis.
    Mesa RA
    Curr Hematol Malig Rep; 2010 Jan; 5(1):15-21. PubMed ID: 20425392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
    Morsia E; Gangat N
    Expert Opin Ther Targets; 2021 Mar; 25(3):211-222. PubMed ID: 33844952
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel therapeutics and targets in myelofibrosis.
    Waksal JA; Harrison CN; Mascarenhas JO
    Leuk Lymphoma; 2022 May; 63(5):1020-1033. PubMed ID: 34852713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing disease burden in patients with classic MPNs.
    Geyer H; Mesa RA
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving symptom burden and quality of life in patients with myelofibrosis: current strategies and future directions.
    Yoon J; Pettit K
    Expert Rev Hematol; 2021 Jul; 14(7):607-619. PubMed ID: 34148506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of JAK inhibitors for low-risk myelofibrosis.
    Alimam S; McLornan D; Harrison C
    Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of myelofibrosis.
    Vannucchi AM
    Hematology Am Soc Hematol Educ Program; 2011; 2011():222-30. PubMed ID: 22160038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.
    Harrison CN; McLornan DP
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):489-497. PubMed ID: 29222297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.